NEW YORK (GenomeWeb News) – Ariosa Diagnostics has filed a regulatory document with the US Securities and Exchange Commission for an initial public offering.

In its preliminary prospectus filed with the SEC on Monday, the San Jose, Calif.-based developer of non-invasive prenatal tests said it intends to offer $69 million in a proposed maximum aggregate offering price. It has not priced its shares yet or said how many share it plans to offer.

Ariosa said that it plans to list its shares on the Nasdaq Global Market under ticker symbol "AROS."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.